# Thomas Karagiannis

List of Publications by Year
in descending order

| | | | |
|---|---|---|---|
| 38 papers | 2,658 citations | 430442 18 h-index | 329751 37 g-index |
| 38 all docs | 38 docs citations | 38 times ranked | 3238 citing authors |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1 | Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Annals of Internal Medicine, 2013, 159, 262. | 2.0 | 749 |
| 2 | Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ: British Medical Journal, 2012, 344, e1369-e1369. | 2.4 | 356 |
| 3 | Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 361, k1310. | 2.4 | 294 |
| 4 | Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2020, 173, 278-286. | 2.0 | 182 |
| 5 | Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 2014, 16, 984-993. | 2.2 | 176 |
| 6 | Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Advances in Drug Safety, 2014, 5, 138-146. | 1.0 | 96 |
| 7 | Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, 2022, 65, 1251-1261. | 2.9 | 93 |
| 8 | Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2116-2124. | 2.2 | 79 |
| 9 | Semaglutide for type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2255-2263. | 2.2 | 71 |
| 10 | Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2015, 17, 1065-1074. | 2.2 | 61 |
| 11 | GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2021, 174, 108737. | 1.1 | 61 |
| 12 | Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 2020, 22, 335-345. | 2.2 | 54 |
| 13 | Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1857-1868. | 2.2 | 44 |
| 14 | Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2016, 52, 458-480. | 1.1 | 42 |
| 15 | Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. Annals of Internal Medicine, 2018, 169, 165. | 2.0 | 38 |
| 16 | Glucagon‐like peptide‐1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 2019, 21, 188-193. | 2.2 | 33 |
| 17 | A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2014, 63, 584-592. | 1.5 | 27 |
| 18 | Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2015, 6, 61-67. | 1.4 | 26 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 19 | Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy, 2017, 18, 843-851. | 0.9 | 19 |
| 20 | Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2022, 24, 106-114. | 2.2 | 19 |
| 21 | Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. BMJ Open, 2016, 6, e012185. | 0.8 | 18 |
| 22 | Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2395-2401. | 2.2 | 18 |
| 23 | Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 822-831. | 2.2 | 17 |
| 24 | Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety, 2016, 7, 36-38. | 1.0 | 13 |
| 25 | Metformin exposure and survival in head and neck cancer: A large population-based cohort study. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 588-594. | 0.7 | 13 |
| 26 | Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. European Journal of Haematology, 2017, 98, 563-568. | 1.1 | 10 |
| 27 | Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 281-289. | 0.9 | 10 |
| 28 | GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Research and Clinical Practice, 2021, 177, 108921. | 1.1 | 10 |
| 29 | Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta-analysis. Diabetic Medicine, 2019, 36, 557-568. | 1.2 | 9 |
| 30 | Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. Journal of General Internal Medicine, 2020, , 1. | 1.3 | 7 |
| 31 | Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence, 2017, Volume 12, 1-10. | 4.7 | 5 |
| 32 | Premixed insulin regimens for type 2 diabetes. Endocrine, 2016, 51, 387-389. | 1.1 | 2 |
| 33 | Meta-analysis of artificial pancreas trials: methodological considerations. Lancet Diabetes and Endocrinology,the, 2017, 5, 685. | 5.5 | 2 |
| 34 | Authors' reply to Scheffel and Schaan. BMJ, The, 2012, 344, e2922-e2922. | 3.0 | 1 |
| 35 | Review: Sodium–glucose cotransporter 2 inhibitors reduce $HbA_{1c}$ and weight but increase infections. Annals of Internal Medicine, 2014, 160, JC10. | 2.0 | 1 |
| 36 | In type 2 diabetes, weekly semaglutide reduced $HbA_{1c}$ and increased weight loss more than weekly exenatide ER. Annals of Internal Medicine, 2018, 168, JC46. | 2.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2021, 174, 141. | 2.0 | 1 |
| 38 | Most add-on therapies to metformin have similar effects on HbA1c. Evidence-Based Medicine, 2016, 21, 223-223. | 0.6 | 0 |